Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

This clinical study will be a 12-week, multicenter, double-blind, placebo-controlled,
randomized withdrawal study in pediatric outpatients with autism, Asperger's Disorder, or
Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) conducted at approximately
180 study centers. Patients who completed at least 12 weeks of study drug exposure during
lead-in study MEM-MD-91 and meet protocol specified responder criteria.

Inclusion Criteria:

1. Completed at least 12 weeks of exposure to study drug in lead-in study MEM-MD-91

2. Met responder criterion at two consecutive visits separated by at least two weeks in
lead-in study MEM-MD-91

3. Provide written informed assent, when developmentally appropriate, to participate in
the study before conduct of any study-specific procedures. The parent/guardian/LAR
must provide written informed consent before the patient's participation in the study.
A separate written informed consent for the caregiver must also be obtained before the
conduct of any study specific procedures

4. Have a knowledgeable caregiver who is capable of providing reliable information about
the patient's condition, attending all clinic visits with the patient, and overseeing
the administration of study drug. Every effort should be made to maintain the same
caregiver as used in the lead-in study throughout this study

5. Have normal results from the physical examination, laboratory tests, ECG, and vital
signs at Visit 1 of this study (last visit of Study MEM-MD-91). Any abnormal findings
must be deemed not clinically significant by the Investigator and documented

6. Be able to speak and understand English sufficiently (or their native language if this
can be accommodated by the site), as well as have a caregiver and parent/guardian/LAR
who is able to speak and understand English sufficiently (or their native language if
this can be accommodated by the site), to comprehend the nature of the study and to
allow for the completion of all study assessments

7. Have a family that is sufficiently organized and stable to guarantee adequate safety
monitoring and continuous attendance to clinic visits for the duration of the study

8. Females who are 9 years and older or who have had onset of menses must have a negative
urine pregnancy test at Visit 1

Exclusion Criteria:

1. Patients with a concurrent medical condition that might interfere with the conduct of
the study, confound interpretation of the study results, or endanger the patient's
well being

2. Significant risk of suicidality

3. Patients with evidence or history of malignancy (other than excised basal cell
carcinoma) or any significant hematologic, endocrine, cardiovascular (including any
rhythm disorder), neurologic, respiratory, renal, hepatic, or gastrointestinal disease

4. Female patients of child-bearing potential who are not using or not willing to use a
conventional method of contraception approved by the PI. Abstinence is an acceptable
method of contraception

5. Patients requiring treatment with prohibited concomitant medications

6. Patients who, in the opinion of the Investigator, might not be suitable for the study

7. Employee or immediate relative of an employee of Forest Laboratories, Inc., any of its
affiliates or partners, or the study center